Helmy, Hamza & Partners, Baker McKenzie's Cairo office, recently advised global healthcare company GlaxoSmithKline Services Unlimited (GSK Group) on the separation of its consumer healthcare business to form global consumer healthcare company - Haleon. The transaction was valued at GBP 55 Million (1.6 Billion EGP). The separation of the Consumer Healthcare project was completed on 18 July 2022.
Ghada El Ehwany, Partner and Head of Corporate and Commercial, said: "We are proud to have advised GSK on this significant a transaction in the global healthcare sector. The demerger unlocks the potential for growth for both GSK and newly listed Haleon. This growth will enable increased access to innovative healthcare for billions of people around the world."
The Helmy, Hamza & Partners, Baker McKenzie Cairo transaction team was led by Partner Ghada El Ehwany and Counsel Mostafa El Sakaa, associates: Moataz El Sherbini and Walid Enany.